Autopsy report · NCT05145452
n-3 Polyunsaturated Fatty Acids to Prevent and Treat Diabetic Neuropathy
Cause of deathStaffing, sites or logistics
“Due to the COVID-19 pandemic, enrollment was interrupted. The intervention pills expired and unable to obtain more.”
Life of this trial
- Registered 6 months before it started.
- Ran for about 2 years 5 months before it stopped.
- 31 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Na
- Sponsor
- University of Missouri-Columbia
- Sponsor type
- University, hospital or other
- Conditions
- Diabetic Neuropathies
- Interventions
- Fish-oil derived n-3 polyunsaturated fatty acids
- Participants
- 31
- Sites
- 2
- Countries
- United States
Trials that died the same way
- Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
“Enrollment halted prematurely due to the Covid-19 pandemic” - Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases
“Enrollment was affected due to the COVID-19 pandemic” - Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients
“enrollment halted in order to have all patients complete follow-up by Jan 2011” - Internet Cognitive Behavioral Therapy for Insomnia to Prevent Cardiovascular Disease
“Intervention services were suspended and then unavailable.” - Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab
“Due to enrollment difficulties compounded by the COVID pandemic.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.